ProciseDx wins CE Mark for point-of-care tests

By staff writers

September 10, 2020 -- Nestlé Health Science subsidiary ProciseDx has received the European CE Mark for Procise IFX and Procise ADL, the company's infliximab and adalimumab point-of-care diagnostics.

Procise IFX and Procise ADL provide diagnostic data for therapeutic drug monitoring within five minutes of a finger-prick blood sample, the company noted. Both tests run on the ProciseDx system, which is about the size of a shoe box.

ProciseDx moves forward with CRP test
Nestlé Health Science subsidiary ProciseDx said that it has submitted a 510(k) application for its Procise point-of-care C-reactive protein (CRP) test...
Nestle's ProciseDx inks technology deal with Lumiphore
Nestlé Health Science subsidiary ProciseDx is set to use Lumiphore's metal luminescent reporter technology in a broad range of rapid point-of-care...

Copyright © 2020

Last Updated ls 9/21/2020 8:42:48 AM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.